2020
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial
Weiss M, Macklin E, McIlduff C, Vucic S, Wainger B, Kiernan M, Goutman S, Goyal N, Rutkove S, Ladha S, Chen I, Harms M, Brannagan T, Lacomis D, Zivkovic S, Ma M, Wang L, Simmons Z, Rivner M, Shefner J, Cudkowicz M, Atassi N, Group F. Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle & Nerve 2020, 63: 371-383. PMID: 33340120, PMCID: PMC8513796, DOI: 10.1002/mus.27146.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmyotrophic Lateral SclerosisAxonsCortical ExcitabilityDouble-Blind MethodElectrodiagnosisElectromyographyEvoked Potentials, MotorFemaleHumansMaleMedian NerveMexiletineMiddle AgedNeural ConductionPreliminary DataTranscranial Magnetic StimulationVoltage-Gated Sodium Channel BlockersConceptsEffects of mexiletineResting motor thresholdSporadic amyotrophic lateral sclerosisRandomized controlled trialsAxonal hyperexcitabilityAmyotrophic lateral sclerosisRandomized to placeboAxonal excitability studiesCompared to placeboPhase II randomized controlled trialSecondary outcome measuresTranscranial magnetic stimulationPrimary endpointLateral sclerosisAxonal excitabilityHalf-timeTreated subjectsMexiletineReduction of motorControlled trialsHyperexcitabilityALS subjectsAlternative causesMagnetic stimulationOutcome measures
2017
Clinical and neuropathological features of ALS/FTD with TIA1 mutations
Hirsch-Reinshagen V, Pottier C, Nicholson A, Baker M, Hsiung G, Krieger C, Sengdy P, Boylan K, Dickson D, Mesulam M, Weintraub S, Bigio E, Zinman L, Keith J, Rogaeva E, Zivkovic S, Lacomis D, Taylor J, Rademakers R, Mackenzie I. Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Acta Neuropathologica Communications 2017, 5: 96. PMID: 29216908, PMCID: PMC5719900, DOI: 10.1186/s40478-017-0493-x.Peer-Reviewed Original ResearchConceptsT-cell-restricted intracellular antigen 1Frontotemporal dementiaTDP-43TDP-43 pathologyAmyotrophic lateral sclerosisLanguage impairmentMotor neuronsPattern of neurodegenerationPsychiatric featuresSporadic ALSFrontotemporal lobar degenerationPyramidal motor systemTDP-43 proteinopathyDiagnosis of amyotrophic lateral sclerosisSporadic amyotrophic lateral sclerosisCaudate atrophyFeatures of amyotrophic lateral sclerosisRepeat expansionRestriction patternsInitial presentationMotor systemMutation carriersFocal weaknessDisease durationClinical phenotype